Jessica Steen, OD: AbbVie/Allergan: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Alcon: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Astellas: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Balance Ophthalmics: Consulting Fees (); Bausch + Lomb: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Carl Zeiss Meditec: Consulting Fees (), Speaker's Bureau (honoraria or other compensation) (); Clearside Biomedical: Ownership Interest (stocks, stock options, patent or other intellectual property or other ownership interest excluding diversified mutual funds) (); Dompe: Speaker's Bureau (honoraria or other compensation) (); Eyenovia: Consulting Fees (); Glaukos: Consulting Fees (); iCare: Consulting Fees (); Ocuterra: Consulting Fees (); Opus Genetics: Consulting Fees (); Orasis: Consulting Fees (); Radius: Consulting Fees (); Tarsus: Consulting Fees (); Thea Pharma: Speaker's Bureau (honoraria or other compensation) (); Viatris: Advisory Committee/Board Member (), Speaker's Bureau (honoraria or other compensation) ()
This case-based course explores the complexities of diagnosing and managing challenging clinical scenarios in glaucoma care. Participants will delve into the intricacies of secondary glaucomas, strategies for detecting disease progression, and the effective integration of advanced ancillary technologies to optimize patient outcomes.
Learning Objectives:
Upon conclusion of this activity, attendees will be able to:
Evaluate risk factors for the development of glaucoma and risk factors for progression
Appreciate the individualized approach to the evaluation and management of individuals with glaucoma
Apply medical evidence through recent notable publications into clinical care
Appraise artifacts and pitfalls of ancillary tests
